Siegall Clay B's Form 4 filing
Immunome Inc. (IMNM) · filed May 21, 2024
- Accession no.
- 0001415889-24-013935
- Filed
- May 21, 2024
- Trade date
- May 20-21, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $1.39M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Siegall Clay BCIK 0001167496 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 20, 2024 | Common Stock | PPurchaseAcquired | +79,566 | $13.91 | +$1,106,763.06 | 399,202 | Direct | |
| May 21, 2024 | Common Stock | PPurchaseAcquired | +20,434 | $13.78 | +$281,580.52 | 419,636 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.